CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
43.16
2.68%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.14
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.02)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 44.35
Open 44.01
1-Year Change 72.86%
Day's Range 42.8 - 44.01
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 13, 2024 43.16 -0.80 -1.82% 43.96 44.45 42.71
Dec 12, 2024 44.35 1.33 3.09% 43.02 45.00 43.02
Dec 11, 2024 43.47 0.43 1.00% 43.04 44.10 42.97
Dec 10, 2024 42.95 0.76 1.80% 42.19 43.83 41.97
Dec 9, 2024 42.71 -0.85 -1.95% 43.56 44.46 41.63
Dec 6, 2024 44.06 -0.29 -0.65% 44.35 45.90 43.45
Dec 5, 2024 42.75 1.31 3.16% 41.44 43.25 41.44
Dec 4, 2024 44.04 1.08 2.51% 42.96 44.41 42.95
Dec 3, 2024 43.58 0.26 0.60% 43.32 43.61 42.53
Dec 2, 2024 44.04 1.31 3.07% 42.73 44.38 42.65
Nov 29, 2024 42.84 -0.11 -0.26% 42.95 43.44 42.84
Nov 27, 2024 42.82 -0.25 -0.58% 43.07 44.01 42.28
Nov 26, 2024 42.78 2.62 6.52% 40.16 42.80 40.16
Nov 25, 2024 41.00 0.95 2.37% 40.05 41.24 39.84
Nov 22, 2024 39.44 0.74 1.91% 38.70 39.69 37.95
Nov 21, 2024 38.88 -0.30 -0.77% 39.18 39.76 38.45
Nov 20, 2024 39.13 0.07 0.18% 39.06 39.49 38.48
Nov 19, 2024 39.10 3.13 8.70% 35.97 39.13 35.97
Nov 18, 2024 36.66 0.66 1.83% 36.00 37.21 35.67
Nov 15, 2024 35.89 -1.12 -3.03% 37.01 37.31 35.29

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Veracyte Inc Company profile

About Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).

Equity composition

Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%

Industry: Bio Diagnostics & Testing

6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

ETH/USD

3,916.50 Price
+1.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.46 Price
+4.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01229

Gold

2,648.80 Price
-1.210% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee 0.0043%
Overnight fee time 22:00 (UTC)
Spread 0.60

BTC/USD

101,985.75 Price
+2.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading